Background Wiskott-Aldrich syndrome (WAS) is a severe X-linked immunodeficiency
characterized by microthrombocytopenia, eczema, recurrent infections, and susceptibility to
autoimmunity and lymphomas. Hematopoietic stem cell transplantation is the treatment of
choice; however, administration of WAS gene–corrected autologous hematopoietic stem
cells has been demonstrated as a feasible alternative therapeutic approach. Objective
Because B-cell homeostasis is perturbed in patients with WAS and restoration of immune …